Option chain shows key data for Thermo Fisher Scientific's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) Stock, Option Chain

Thermo Fisher Scientific

NASDAQ:ADBE

NASDAQ:DELL

NASDAQ:INTC

NYSE:AET

NYSE:AKS

nyse:bac

NYSE:CAT

NYSE:CML

NYSE:CVX

NYSE:DIS

NYSE:FDX

NYSE:GAP

NYSE:HPQ

NYSE:JPM

nyse:mcd

NYSE:RIO

NYSE:SLB

NYSE:TMO

NYSE:WLP

nyse:wmt

Late Slide Derails Nasdaq Hot Streak

NYSE:GE

Dow Targets New &#39;10 High, Nasdaq Inches Higher

Strategy anchored on early clinical development of proprietary assets with single-agent potential:
<ul>
<li>Drive innovation with first-in-class ANKET&#xAE; NK-cell engager Platform</li>
<li>Accelerate development of differentiated Antibody-Drug Conjugates</li>
<li>Advance current late-stage assets through partnerships</li>
</ul>

News

IPHA

Innate Pharma Unveils Transformative Strategy Focused On ANKET Platform, ADC Development, And Strategic Partnerships

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2024</td>
<td>2023</td>
<td>$ Increase</td>
<td colspan="1">% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended December 31,</td>
<td>$7.8 million</td>
<td>$5.1 million</td>
<td>$2.7 million</td>
<td>52%</td>
</tr>
<tr>
<td>During the Years Ended December 31,</td>
<td>$26.5 million</td>
<td>$17.5 million</td>
<td>$9.0 million</td>
<td>52%</td>
</tr>
</tbody>
</table>
</figure>
 During the three-month period ended December 31, 2024, annualized production output was approximately 103% of the Company's estimated full capacity of approximately $30 million per year. This production output helped reduce the backlog of orders to approximately $4.4 million as of January 1, 2025 from approximately $9.4 million as of January 1, 2024. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of peak calving season during the first quarter.

ICCC

Reported Earlier, ImmuCell Preliminary Q4 Sales Of $7.8M (+52% YoY) and Fiscal 2024 Of $26.5M (+52% YoY), Driven by Increased Production

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.starlux-airlines.com%2F&amp;esheet=54175823&amp;newsitemid=20250109390603&amp;lan=en-US&amp;anchor=STARLUX+Airlines&amp;index=1&amp;md5=53df885c74706717944ce68bd7a7233b">STARLUX Airlines</a>, in partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.airbus.com%2Fen&amp;esheet=54175823&amp;newsitemid=20250109390603&amp;lan=en-US&amp;anchor=Airbus&amp;index=2&amp;md5=2600c2d3633ad69892f28b7ac70211af">Airbus</a>, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rolls-royce.com%2F&amp;esheet=54175823&amp;newsitemid=20250109390603&amp;lan=en-US&amp;anchor=Rolls-Royce&amp;index=3&amp;md5=bd3bcd17be70c33e5d365226d8d46d0c">Rolls-Royce</a>, today announced the execution of an option for five A350F freighters, doubling its freighter fleet to 10 aircraft. This strategic move positions STARLUX as one of the largest purchasers of the A350F model. This order builds upon the purchase agreement signed last year at the 2024 Singapore Airshow. A formal signing ceremony held at the STARLUX Flight Operations Center in Taiwan marked the formalization of the purchase agreement.

EADSF

European Aeronautic Defence And Space Unsponsored

EADSY

RYCEY

Reported Earlier, STARLUX Airlines Expands Freighter Fleet with Order for Five Additional Airbus A350F Aircraft

Barnes Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) ("Barnes" or "the Company"), a global provider of highly engineered products, differentiated industrial technologies and innovative solutions, today announced that its shareholders voted to approve the Company's previously announced acquisition by funds managed by affiliates of Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) ("Apollo") (the "Apollo Funds") at the Company's Special Meeting of Shareholders (the "Special Meeting"). Under the terms of the merger agreement, subject to the completion of the transaction, Barnes stockholders will receive $47.50 per share in cash for every share of Barnes common stock they own immediately prior to the effective time of the merger.
Approximately 99% of the total shares voted at the Special Meeting were voted in favor of the transaction, which represented approximately 80% of the total outstanding shares of Barnes common stock as of December 6, 2024, the record date for the Special Meeting.

Reported Earlier, Barnes Group Shareholders Approve $47.50 Per Share Acquisition by Apollo Global Management

Today, investment funds managed by KKR, a leading global investment firm, and the Public Sector Pension Investment Board ("PSP Investments"), one of Canada's largest pension investors, announced an agreement to acquire a 19.9% interest in American Electric Power's ("AEP") Ohio and Indiana &amp; Michigan transmission companies for $2.82 billion. Founded in 1906 and one of the largest electric utilities in the U.S., AEP has pioneered the country's energy system through the delivery of safe, reliable and affordable energy for millions of homes. The investment will support AEP's ability to meet increasing customer demand and enhance grid reliability. KKR and PSP Investments have formed a 50/50 strategic partnership to pursue the acquisition.

Reported Earlier, KKR and PSP Investments Acquire 19.9% Stake in AEP's Transmission Companies for $2.82B

There is no action required by the company's shareholders with respect to the ticker symbol change. The company's Class A common stock will continue to be listed on the NYSE and the company's CHESS Depository Interests (CDIs) will continue to be listed on the ASX. The CUSIP for the NYSE listing and the ISIN for the ASX listing will remain unchanged.

Reported Earlier, Block, Inc. To Change Ticker Symbol To 'XYZ' On NYSE Effective January 21 And On ASX Effective January 22

<a href="https://www.globenewswire.com/Tracker?data=R5rU-PI08fc3ZS_SKLnG3KUrIZqTbWeevmDh06kewS0DbEweqL-hdz0wcPdVI8rY21hrqlT5KE8s-O4bTshZe5RS9mlBsuxNLzVqeaZ8CMA=">Toll Brothers, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>), the nation's leading builder of luxury homes, today announced its newest community,&nbsp;<a href="https://www.globenewswire.com/Tracker?data=oNmoneybkl_7FDdK_CEaX4ClK155dCYnz3yfMBIK8aCY5QteCDgAwMWVruGEbv6GlGVCVCt7fJUdJ4K_R0A1FTKQ1loUeVulU00lzO8NYXDjhiUKaHOT1LqSAFCMPSUdsDELs1DyDDDBWHj1z_bS8n445TYZ7v7XdktY8h9xffs=">Longleaf Meadow</a>, is coming soon to Fuquay-Varina, North Carolina. This exclusive Toll Brothers neighborhood will include just 47 single-family home sites offering top-tier options for personalization at the Toll Brothers Design Studio. Site work is underway, and the community is anticipated to open for sale in early 2025.
Home buyers will choose from six stunning two-story home designs with large, open floor plans ranging from 3,995 to 5,200+ square feet. The homes include 4 to 6 bedrooms, 3 to 5.5 baths, 2- to 4-car garages, and optional features designed for today's lifestyles such as flex rooms, offices, and lofts. Homes will be priced from upper $800,000s.
 &nbsp;

Reported Earlier, Toll Brothers to Launch Longleaf Meadow: Exclusive 47-Home Luxury Community in Fuquay-Varina, NC by 2025

<ul>
<li>Realigning resources to extend runway to mid-2027</li>
<li>Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025</li>
<li>Exploring partnerships for continued development of Lunre+Camo and other assets</li>
</ul>
Cash Position and Financial Guidance:
Repare ended 2024 with approximately $153 million in cash, cash equivalents and marketable securities, which is anticipated with the implementation of the cost-saving measures announced above to fund the Company's streamlined operations into mid-2027.

RPTX

Reported Earlier, Repare Therapeutics Focuses On RP-1664 And RP-3467, Seeks Partners For Lunre+Camo, And Reports $153M Cash On Hand

<a href="https://www.globenewswire.com/Tracker?data=m6LVsFHlhK4xrbOjCL6f3Y7qTMj74Db-FZdTqmR-d_hz50lWtWamjLxPhJCyCWss83xEsQ0mt-k8TacKl8Cl0IXEXASo3YGdJxGt5lVOmfI=">Toll Brothers, Inc</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>), the nation's leading builder of luxury homes, today announced its newest D.C. Metro area community, <a href="https://www.globenewswire.com/Tracker?data=uyKFIpL9ouKNhYvfz4sjGx4baA21rEB4tNGxq1V4lZlhIaffUe27g0fsAZApnUC9UaGGiw82k_U2HFcemx9hFZJpgMGuFAtv-UbRO0BxSdLD9Mco9MBmav7UXeRxTw3DCxVyvyY1KPd3oMiO1Dxsc0noZEm4LZ1p7SX92JwVNgc=">Chevy Chase Crossing</a>, is coming soon to Maryland. This exclusive Toll Brothers neighborhood will feature two distinct collections of luxury townhomes, perfectly designed for modern living and situated along the anticipated new Purple Line transit system. The community will be located at Manor Road and Erdem Place in Chevy Chase and is anticipated to open in early 2025.
Chevy Chase Crossing will offer luxurious townhomes with spacious floor plans ranging from more than 2,400 to over 3,600 square feet, including 3 to 4 bedrooms, two-car garages, and options for elevators. Each home is designed to provide an exceptional living experience with features such as open kitchen/great room combos, luxurious primary bedroom suites, spacious secondary bedrooms, convenient bedroom-level laundry rooms, and flex rooms. Homes will be priced from $1.7 million.

Reported Earlier, Toll Brothers Announces Chevy Chase Crossing: Luxury Townhome Community Near D.C. Metro, Opening in 2025

<a href="https://www.globenewswire.com/Tracker?data=12CsIRv3JJlHPK-1CjIDKPp6hrKr8nyhsQQ8wgMlkPDDZQYiYDSKzO_tflpY6N0KhQMJCZP0kF-fa2ECmwUOlCSHT00XVkVdT4PUFozPmhI=">Toll Brothers, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>), the nation's leading builder of luxury homes, today announced the upcoming opening of its new&nbsp;<a href="https://www.globenewswire.com/Tracker?data=gc19oI2RYHKmgRaZrvd4815iCDGWOin6gHdD-qPfSZGe3m4Vwa6OrzUZbvwN-JEZXl0Ly0bHww8e3_OPupTYpXzO6IF90_wr27p5rj47QGFFKfxzVQFPMxkECs1V6XJfNG2P1qjbwbQp_cJ4ELZPk3nuin02jy6_CsDEpnVD8RLl-nzwhJ1pJPXpx1Yse4g2">Saddlecrest at Windermere</a>&nbsp;community in Windermere, Florida. This exclusive Orlando-area community will feature luxury single-family homes situated on up to half-acre home sites, many with water views and direct access to Lake Roberts. Construction is underway on the new Toll Brothers model home, and the community is expected to open for sales in spring 2025.

Reported Earlier, Toll Brothers to Launch Saddlecrest at Windermere: Luxury Lakefront Living Coming to Orlando Area in 2025

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4337434-1&amp;h=175162631&amp;u=http%3A%2F%2Fwww.jll.com%2F&amp;a=JLL">JLL</a>'s Capital Markets group announced today it has arranged a $300 million refinancing for the Omni Nashville Hotel, an 800-key luxury hotel in downtown Nashville.
JLL worked on behalf of the borrower, TRT Holdings, Inc., to secure a fixed-rate, seven-year loan through a U.S.-based insurance company and AllianceBernstein Commercial Real Estate Debt, in its capacity as advisor to Equitable Financial Life Insurance Company.
The 21-story Omni Nashville Hotel opened in 2013 and features over 80,000 square feet of meeting space, including Nashville's largest hotel ballroom at 23,800 square feet. The LEED Silver certified property offers multiple dining options like Bob's Steak &amp; Chop House, Kitchen Notes and Barlines, as well as a 5,500-square-foot Mokara spa, rooftop pool and state-of-the-art fitness center.
Located at 250 Rep. John Lewis Way South, the hotel is seamlessly integrated with the Country Music Hall of Fame and Museum and sits across from the 2.1 million-square-foot Music City Center convention facility. The property benefits from Nashville's booming tourism and corporate sectors, with over 14 million annual visitors and major employers expanding in the market.

Reported Earlier, JLL Secures $300M Refinancing for Omni Nashville Hotel, Boosting Downtown Landmark's Growth Potential

<ul>
<li>QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targets</li>
<li>No instrument hardware changes required for upgraded capability thanks to new QIAcuity Software 3.1 update and launch of QIAcuity High Multiplex Probe PCR Kit</li>
<li>New QIAcuity digital PCR capabilities helps make lab work more productive and cost-efficient through savings on time, reagents consumption and use of precious sample materials</li>
</ul>

QGEN

QIAGEN Enhances QIAcuity Digital PCR With High-Order Multiplexing For Simultaneous Detection Of Up To12 Targets

Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced its strategic priorities and key anticipated 2025 milestones that support the Company's mission to transform the lives of patients and bring forth a new era in medicine.
Recent Pipeline Advancement and Corporate Updates
<ul>
<li>Strategic Reorganization Focused on Key Value Drivers:
<ul>
<li>The pipeline prioritization is intended to focus resources on high value programs - NTLA-2002 and nex-z - to ensure efficient execution, achieve near-term clinical milestones, and prepare Intellia for commercial launch. As part of this prioritization, the Company discontinued development of NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency-associated lung disease and select research-stage programs. Over the course of 2025, the strategic reorganization will result in a net workforce reduction of approximately 27%.</li>
<li>The Company expects to incur charges of approximately $8 million associated with the reorganization, which are anticipated to be incurred in the first quarter of 2025.</li>
<li>Intellia ended the fourth quarter of 2024 with approximately $862 million in cash, cash equivalents and investments. The combination of its cash balance and the anticipated cost savings are expected to provide the Company with cash runway into the first half of 2027.</li>
<li>Laura Sepp-Lorenzino, Ph.D., Intellia's Chief Scientific Officer, has announced her retirement effective December 31, 2025 after more than 30 years of service in the biopharmaceutical industry and academia. Dr. Sepp-Lorenzino will transition from her role as CSO and continue as a Senior Scientific Advisor for the remainder of the year. "I would like to thank Laura for her service to Intellia. She has been a tireless innovator and advocate for the promise of gene editing, and we look forward to continuing the work and vision she championed," said John Leonard M.D., President and Chief Executive Officer of Intellia.</li>
<li>The Company also announced that Birgit Schultes, Ph.D., who has been leading Immunology and Cell Therapy since 2017, will be promoted to Executive Vice President and Chief Scientific Officer, effective January 13, 2025. Dr. Schultes has over 20 years of experience in drug development and biotechnology, including the clinical development of cell therapies and complex biologic products. Dr. Schultes received her M.S. in biology and Ph.D. in immunology from the University of Bonn, Germany, and completed the Advanced Management Development Program at the Boston University Questrom School of Business.</li>
</ul>
</li>
<li>NTLA-2002 for Hereditary Angioedema (HAE):
<ul>
<li>Patients are actively enrolling in the pivotal Phase 3 HAELO study.</li>
<li>Presented clinical data, in October at the 2024 American College of Allergy, Asthma &amp; Immunology (ACAAI) Scientific Meeting, from the Phase 2 study that demonstrated the potential of NTLA-2002 to end chronic, prophylaxis treatment and provide freedom from attacks following a one-time infusion.</li>
</ul>
</li>
<li>Nex-z for Transthyretin (ATTR) Amyloidosis:
<ul>
<li>Strong enrollment and momentum continue in the Phase 3 MAGNITUDE study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), tracking ahead of the Company's target enrollment projections.</li>
<li>Patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) are actively screening in the Phase 3 MAGNITUDE-2 study.</li>
<li>Presented first clinical evidence, in November at the 2024 American Heart Association (AHA) Scientific Sessions, that consistent, rapid, deep and durable reductions in serum TTR achieved after a one-time treatment of nex-z may halt, and potentially reverse, disease progression.</li>
</ul>
</li>
</ul>
Strategic Priorities and Anticipated 2025 Milestones
Intellia's strategic priorities reflect the Company's ongoing evolution from a late-stage development company to a commercial-ready organization by the end of 2026.
1. Drive focused clinical execution to complete or accelerate enrollment in the pivotal studies of NTLA-2002 and nex-z
<ul>
<li>NTLA-2002 for HAE: 
<ul>
<li>Dose the first patient in the pivotal Phase 3 HAELO trial in 1Q25.</li>
<li>Complete HAELO enrollment in second half of 2025.</li>
<li>Present longer-term data from the Phase 1/2 study – data will include patients in the Phase 2 portion who initially received a 25 mg dose or placebo and were subsequently given the 50 mg dose of NTLA-2002 selected for the Phase 3 study</li>
</ul>
</li>
<li>Nex-z for ATTR amyloidosis:
<ul>
<li>Dose the first patient in the pivotal Phase 3 MAGNITUDE-2 trial for ATTRv-PN in 1Q25.</li>
<li>Enroll at least 550 patients cumulatively within the MAGNITUDE trial for ATTR-CM.</li>
<li>Present longer-term data from both ATTR-CM and ATTRv-PN patients in the Phase 1 study – data will include updated measures of clinical efficacy and safety. &nbsp;</li>
</ul>
</li>
</ul>
2.&nbsp;Advance commercial readiness by implementing core commercialization and medical capabilities for initial launch in the U.S.
<ul>
<li>Complete buildout of the commercial leadership team by second half of 2025. &nbsp;</li>
<li>Expand the reach of medical education activities in HAE and ATTR amyloidosis in partnership with key medical societies and patient organizations.</li>
<li>Initiate pre-approval information exchange to allow payers to begin planning for coverage and formulary decisions.</li>
</ul>

NTLA

Reported Earlier, Intellia Therapeutics Reorganizes Pipeline, Prioritizes Key Gene-Editing Programs, and Reduces Workforce by 27%

<ul>
<li>New QIAstat-Dx Gastrointestinal Panel 2 Mini B&amp;V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions</li>
<li>QIAGEN the first to offer both comprehensive and targeted syndromic gastrointestinal panels, giving clinicians unmatched flexibility to optimize diagnostics for individual patients</li>
<li>QIAstat-Dx Rise higher-capacity instrument version to be submitted in early 2025 for U.S. regulatory clearance, builds on groundbreaking 2024 clearances of four QIAstat-Dx Panels</li>
</ul>

Reported Earlier, QIAGEN Gains FDA Clearance For QIAstat-Dx Mini Gastrointestinal Panel, Supporting Year-Round Outpatient Care

<ul>
<li>During the fourth quarter, we acquired 29 new properties for $103.4 million at a weighted average cash capitalization rate of 7.9% and a weighted average lease term of 11.0 years. The acquisitions were spread across 7 industries, 17 tenants, and 16 states, including 12 new tenants and four new states.</li>
<li>Subsequent to quarter-end, we acquired one property for $2.0 million and have signed PSAs for an additional $53.0 million of properties.</li>
<li>On December 30, 2024, we drew down on our $200 million delayed-draw term loan in full. The term loan has a five-year duration after consideration of extension options and bears interest at adjusted SOFR plus 1.2%.</li>
<li>On December 30, 2024, we repaid in full our $253 million ABS notes using proceeds from the $200 million delayed-draw term loan, revolver borrowings, and available cash on hand.</li>
</ul>

Reported Earlier, FrontView REIT Acquires 29 Properties Across 16 States in Q4 for $103.4M, $200M Term Loan Drawdown Enables Full Repayment of ABS Notes, Expands Tenant and Geographic Footprint

PECO

Reported Earlier, Phillips Edison & Company Extends Maturity And Upsizes Revolving Credit Facility To $1B

2024 silver production was 9.68 million ounces, compared with guidance as upwardly revised in October 2024, of 9.2 million ounces to 9.7 million ounces. Silver equivalent production was 15.57 million ounces, slightly above the high end of guidance at 15.5 million ounces as upwardly revised in October 2024. Zinc production of 69.7 million pounds, lead production of 46.4 million pounds, and gold production of 5.53 thousand ounces were all slightly above the high end of guidance, which did not change during 2024.

GATO

Reported Earlier, Gatos Silver Reported 9.68 Million Ounces Of Silver Produced In 2024, Meeting Revised Guidance

Vision Marine Technologies Inc. (the "Company", "Vision Marine", "we", "us", "our") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>), a leading innovator in electric marine propulsion, announces the establishment of a production line for custom cooling plates in partnership with Calip Group, a leader in high-tech welding processes. Under this collaboration, Calip Group will supply components that enhance the thermal management of Vision Marine's high-voltage (HV) marine battery packs. These custom cooling plates are specifically tailored to meet the stringent demands of marine applications, with production slated to begin in 2025.

VMAR

Reported Earlier, Vision Marine Partners with Calip Group to Produce Advanced Cooling Plates for Electric Boat Batteries

<a href="https://www.globenewswire.com/Tracker?data=GEQlO9c5hAxd2jm1q36Vyy9W8TgMiQ8LTdDh8EHqKC_omGk1qlS05LH4cIPt5tD0fyXLPSDIA7u4mTqJkyMkzW8MF_jsSmuPHl1XG-WFCys=">Mural Oncology plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways designed to address areas of unmet need for patients with a variety of cancers, today announced it has reached the 75% of overall survival (OS) events necessary for the planned interim analysis of ARTISTRY-7, its potentially registrational trial of&nbsp;nemvaleukin in combination with pembrolizumab in platinum resistant ovarian cancer (PROC), and that it has extended its cash runway projection into Q1 2026 beyond key upcoming catalysts.
The company expanded its pipeline in Q4 2024, by nominating two development candidates, one for its interleukin-18 (IL-18) program and one for its IL-12 program. MURA-8518 is designed to be a half-life extended, binding protein-resistant IL-18 in order to overcome the native cytokine's limitations as a therapeutic. Mural expects to submit an Investigational New Drug (IND) Application or Clinical Trial Application (CTA) for a phase 1 trial of MURA-8518 in Q4 2025. MURA-7012 is comprised of targeted split IL-12 sub-units that preferentially self-assemble at the tumor site and are designed to limit systemic exposure.

MURA

Mural Oncology Achieves 75% OS Events for ARTISTRY-7 Trial and Extends Cash Runway Through Q1 2026

TSMC ((TWSE: 2330, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) today announced its net revenue for December 2024: On a consolidated basis, revenue for December 2024 was approximately NT$278.16 billion, an increase of 0.8 percent from November 2024 and an increase of 57.8 percent from December 2023. Revenue for January through December 2024 totaled NT$2,894.31 billion, an increase of 33.9 percent compared to the same period in 2023.
<img src="https://pr.tsmc.com/system/files/news/8df762c621bbd0b33a8189472d9fefbc33b0010f/Dec%202024%20%28E%29.jpg" alt="TSMC December 2024 Revenue Report" />

Comments

Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE:TMO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga